Evan F Garner
Overview
Explore the profile of Evan F Garner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
146
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Brener M, Hamandi M, Hong E, Pizano A, Harloff M, Garner E, et al.
J Thorac Cardiovasc Surg
. 2022 Sep;
167(4):1263-1275.e3.
PMID: 36153166
Objective: Implantation of a transcatheter valve-in-mitral annular calcification (ViMAC) has emerged as an alternative to traditional surgical mitral valve (MV) replacement. Previous studies evaluating ViMAC aggregated transseptal, transapical, and transatrial...
2.
Aye J, Stafman L, Williams A, Garner E, Stewart J, Anderson J, et al.
Oncotarget
. 2019 Oct;
10(53):5534-5548.
PMID: 31565187
Aggressive therapies for patients with metastatic Wilms tumor (WT) with subsequent severe late effects warrant the search for novel therapies. The role of focal adhesion kinase (FAK), a non-receptor tyrosine...
3.
Stafman L, Williams A, Marayati R, Aye J, Markert H, Garner E, et al.
Sci Rep
. 2019 Sep;
9(1):13259.
PMID: 31519958
Patient-derived xenografts (PDXs) provide an opportunity to evaluate the effects of therapies in an environment that more closely resembles the human condition than that seen with long-term passage cell lines....
4.
Williams A, Garner E, Stafman L, Aye J, Quinn C, Marayati R, et al.
Transl Oncol
. 2019 Jul;
12(10):1364-1374.
PMID: 31362265
Purpose: In spite of advances in therapy for some subtypes, group 3 medulloblastoma continues to portend a poor prognosis. A subpopulation of medulloblastoma cells expressing the cell surface marker CD133...
5.
Stafman L, Williams A, Garner E, Aye J, Stewart J, Yoon K, et al.
Transl Oncol
. 2018 Nov;
12(2):200-208.
PMID: 30412911
Hepatoblastoma is the most common primary liver tumor in children, but treatment has not changed significantly in the past 20 years. We have previously demonstrated that Proviral Integration site for...
6.
Williams A, Garner E, Waters A, Stafman L, Aye J, Markert H, et al.
Transl Oncol
. 2018 Oct;
12(1):84-95.
PMID: 30286326
High-risk neuroblastoma continues to carry a poor prognosis. Nearly 50% of these tumors relapse following extensive treatment regimens. Protein phosphatase 2A (PP2A), a tumor suppressor, has been shown to be...
7.
Garner E, Stafman L, Williams A, Aye J, Goolsby C, Atigadda V, et al.
J Neurooncol
. 2018 Aug;
140(2):209-224.
PMID: 30132166
Background: Group 3 tumors account for approximately 25-30% of medulloblastomas and have the worst prognosis. UAB30 is a novel synthetic rexinoid shown to have limited toxicities in humans and significant...
8.
Garner E, Valsangkar N, Wang T, Porterfield J, Koniaris L, Chen H
J Surg Res
. 2018 Jun;
229:122-126.
PMID: 29936978
Background: Many surgical departments in the United States lack endocrine surgery faculty. Although endocrine surgeons can provide worthwhile clinical services, it is unclear how they contribute to the overall academic...
9.
Stafman L, Mruthyunjayappa S, Waters A, Garner E, Aye J, Stewart J, et al.
Oncotarget
. 2018 Jun;
9(32):22665-22679.
PMID: 29854306
Increasing incidence coupled with poor prognosis and treatments that are virtually unchanged over the past 20 years have made the need for the development of novel therapeutics for hepatoblastoma imperative....
10.
Garner E, Williams A, Stafman L, Aye J, Mroczek-Musulman E, Moore B, et al.
Sci Rep
. 2018 May;
8(1):6913.
PMID: 29720672
Group 3 tumors account for 28% of medulloblastomas and have the worst prognosis. FTY720, an immunosuppressant currently approved for treatment of multiple sclerosis, has shown antitumor effects in several human...